Home
>
US Stocks
>
Envista Holdings

Envista Holdings (NVST)

$32.96

+0.72

(+2.23%)▲

Market is closed - opens 7 PM, 05 Jun 2023

Insights on Envista Holdings

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 631.1M → 891.7M (in $), with an average increase of 15.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 73.5M → 43.8M (in $), with an average decrease of 40.4% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical Inc has given 43.3% return, outperforming this stock by 67.0%

  • Vs WST

    In the last 3 years, West Pharmaceutical Services, Inc. has given 66.0% return, outperforming this stock by 18.5%

Performance

  • $32.29
    $32.96
    $32.96
    downward going graph

    2.03%

    Downside

    Day's Volatility :2.03%

    Upside

    0.0%

    downward going graph
  • $31.20
    $43.94
    $32.96
    downward going graph

    5.34%

    Downside

    52 Weeks Volatility :28.99%

    Upside

    24.99%

    downward going graph

Returns

PeriodEnvista HoldingsSector (Health Care)Index (Russel 2000)
3 Months
-15.38%
0.9%
-8.3%
6 Months
-1.64%
-6.8%
-6.5%
1 Year
-23.76%
0.4%
-6.1%
3 Years
47.47%
28.3%
21.8%

Highlights

Market Capitalization
5.3B
Book Value
$26.14
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
1.17
PE Ratio
27.56
Wall Street Target Price
44.5
Profit Margin
8.27%
Operating Margin TTM
13.48%
Return On Assets TTM
3.29%
Return On Equity TTM
5.09%
Revenue TTM
2.6B
Revenue Per Share TTM
15.71
Quarterly Revenue Growth YOY
-0.7000000000000001%
Gross Profit TTM
1.5B
EBITDA
488.7M
Diluted Eps TTM
1.17
Quarterly Earnings Growth YOY
-0.4
EPS Estimate Current Year
1.86
EPS Estimate Next Year
2.13
EPS Estimate Current Quarter
0.41
EPS Estimate Next Quarter
0.47

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Envista Holdings(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
14
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 35.01%

Current $32.96
Target $44.50

Company Financials

FY17Y/Y Change
Revenue
2.8B
↑ 0.92%
Net Income
301.1M
↑ 10.7%
Net Profit Margin
10.71%
↑ 0.94%
FY18Y/Y Change
Revenue
2.8B
↑ 1.2%
Net Income
230.7M
↓ 23.38%
Net Profit Margin
8.11%
↓ 2.6%
FY19Y/Y Change
Revenue
2.8B
↓ 3.27%
Net Income
217.6M
↓ 5.68%
Net Profit Margin
7.91%
↓ 0.2%
FY20Y/Y Change
Revenue
2.3B
↓ 17.07%
Net Income
33.3M
↓ 84.7%
Net Profit Margin
1.46%
↓ 6.45%
FY21Y/Y Change
Revenue
2.5B
↑ 9.94%
Net Income
340.5M
↑ 922.52%
Net Profit Margin
13.57%
↑ 12.11%
FY22Y/Y Change
Revenue
2.6B
↑ 2.4%
Net Income
243.1M
↓ 28.6%
Net Profit Margin
9.46%
↓ 4.11%
Q4 FY21Q/Q Change
Revenue
651.8M
↑ 7.33%
Net Income
85.8M
↑ 6.98%
Net Profit Margin
13.16%
↓ 0.05%
Q1 FY22Q/Q Change
Revenue
631.4M
↓ 3.13%
Net Income
74.9M
↓ 12.7%
Net Profit Margin
11.86%
↓ 1.3%
Q2 FY22Q/Q Change
Revenue
645.8M
↑ 2.28%
Net Income
47.1M
↓ 37.12%
Net Profit Margin
7.29%
↓ 4.57%
Q3 FY22Q/Q Change
Revenue
631.1M
↓ 2.28%
Net Income
47.6M
↑ 1.06%
Net Profit Margin
7.54%
↑ 0.25%
Q4 FY22Q/Q Change
Revenue
660.8M
↑ 4.71%
Net Income
73.5M
↑ 54.41%
Net Profit Margin
11.12%
↑ 3.58%
Q1 FY23Q/Q Change
Revenue
891.7M
↑ 34.94%
Net Income
43.8M
↓ 40.41%
Net Profit Margin
4.91%
↓ 6.21%
FY17Y/Y Change
Total Assets
6.0B
-
Total Liabilities
998.2M
-
FY18Y/Y Change
Total Assets
5.8B
↓ 2.52%
Total Liabilities
1.0B
↑ 1.7%
FY19Y/Y Change
Total Assets
6.2B
↑ 5.42%
Total Liabilities
2.6B
↑ 157.63%
FY20Y/Y Change
Total Assets
6.9B
↑ 11.65%
Total Liabilities
3.2B
↑ 20.63%
FY21Y/Y Change
Total Assets
6.6B
↓ 4.39%
Total Liabilities
2.5B
↓ 20.25%
FY22Y/Y Change
Total Assets
6.6B
↑ 0.19%
Total Liabilities
2.4B
↓ 5.41%
Q4 FY21Q/Q Change
Total Assets
6.6B
↑ 0.19%
Total Liabilities
2.5B
↓ 3.77%
Q1 FY22Q/Q Change
Total Assets
6.6B
↓ 0.03%
Total Liabilities
2.5B
↑ 1.0%
Q2 FY22Q/Q Change
Total Assets
6.5B
↓ 1.69%
Total Liabilities
2.4B
↓ 3.79%
Q3 FY22Q/Q Change
Total Assets
6.4B
↓ 0.76%
Total Liabilities
2.5B
↑ 0.37%
Q4 FY22Q/Q Change
Total Assets
6.6B
↑ 2.73%
Total Liabilities
2.4B
↓ 3.01%
Q1 FY23Q/Q Change
Total Assets
6.6B
↓ 0.18%
Total Liabilities
2.3B
↓ 3.53%
FY17Y/Y Change
Operating Cash Flow
359.1M
↓ 13.88%
Investing Cash Flow
-54.9M
↓ 7.58%
Financing Cash Flow
-304.2M
↓ 14.93%
FY18Y/Y Change
Operating Cash Flow
400.1M
↑ 11.42%
Investing Cash Flow
-75.5M
↑ 37.52%
Financing Cash Flow
-324.6M
↑ 6.71%
FY19Y/Y Change
Operating Cash Flow
397.5M
↓ 0.65%
Investing Cash Flow
-78.4M
↑ 3.84%
Financing Cash Flow
-107.7M
↓ 66.82%
FY20Y/Y Change
Operating Cash Flow
283.9M
↓ 28.58%
Investing Cash Flow
-69.1M
↓ 11.86%
Financing Cash Flow
492.5M
↓ 557.29%
FY21Y/Y Change
Operating Cash Flow
391.4M
↑ 37.87%
Investing Cash Flow
232.9M
↓ 437.05%
Financing Cash Flow
-465.6M
↓ 194.54%
Q4 FY21Q/Q Change
Operating Cash Flow
165.8M
↑ 87.77%
Investing Cash Flow
258.8M
↓ 8448.39%
Financing Cash Flow
1.8M
↓ 141.86%
Q1 FY22Q/Q Change
Operating Cash Flow
3.5M
↓ 97.89%
Investing Cash Flow
5.1M
↓ 98.03%
Financing Cash Flow
5.3M
↑ 194.44%
Q2 FY22Q/Q Change
Operating Cash Flow
22.2M
↑ 534.29%
Investing Cash Flow
-591.6M
↓ 11700.0%
Financing Cash Flow
1.8M
↓ 66.04%
Q3 FY22Q/Q Change
Operating Cash Flow
46.7M
↑ 110.36%
Investing Cash Flow
-69.7M
↓ 88.22%
Financing Cash Flow
73.7M
↑ 3994.44%
Q1 FY23Q/Q Change
Operating Cash Flow
3.1M
↓ 97.19%
Investing Cash Flow
-22.0M
-
Financing Cash Flow
-1.5M
↓ 97.8%

Technicals Summary

Sell

Neutral

Buy

Envista Holdings is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Envista Holdings
Envista Holdings
-5.99%
-1.64%
-23.76%
47.47%
17.92%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
2.96%
15.74%
44.24%
65.98%
95.96%
ResMed Inc.
ResMed Inc.
-4.93%
0.59%
4.64%
37.21%
109.87%
Becton, Dickinson and Company
Becton, Dickinson and Company
-0.27%
2.27%
-2.68%
3.38%
10.27%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-6.89%
43.56%
11.23%
67.35%
260.64%
Alcon AG
Alcon AG
8.85%
16.34%
5.26%
24.43%
36.91%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Envista Holdings
Envista Holdings
27.56
27.56
NA
1.86
0.05
0.03
0.0
26.14
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
83.93
83.93
3.27
5.47
0.11
0.07
0.0
32.01
ResMed Inc.
ResMed Inc.
37.32
37.32
1.74
6.52
0.24
0.12
0.01
26.77
Becton, Dickinson and Company
Becton, Dickinson and Company
27.49
27.49
2.31
12.2
6.2
0.03
0.01
90.44
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
46.78
46.78
4.06
7.69
0.22
0.13
0.0
37.42
Alcon AG
Alcon AG
113.94
113.94
NA
2.65
0.02
0.02
0.0
40.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Envista Holdings
Envista Holdings
Buy
$5.3B
17.92%
27.56
8.27%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$108.8B
95.96%
83.93
20.4%
ResMed Inc.
ResMed Inc.
Buy
$32.1B
109.87%
37.32
21.49%
Becton, Dickinson and Company
Becton, Dickinson and Company
Buy
$68.7B
10.27%
27.49
8.6%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$25.4B
260.64%
46.78
19.15%
Alcon AG
Alcon AG
Buy
$39.0B
36.91%
113.94
3.84%

Institutional Holdings

  • BlackRock Inc

    11.34%

  • Vanguard Group Inc

    9.95%

  • Morgan Stanley - Brokerage Accounts

    8.83%

  • Lazard Asset Management LLC

    6.50%

  • Massachusetts Financial Services Company

    6.08%

  • FMR Inc

    5.04%

Company Information

Envista is a global family of more than 30 trusted dental brands, united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services.  Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers an estimated 90% of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. Envista companies, including KaVo Kerr, Nobel Biocare, and Ormco, partner with dental professionals to help them deliver the best possible patient care. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry.

Organization
Envista Holdings
Employees
12700
CEO
Mr. Amir Aghdaei
Industry
Health Technology

Discover More

FAQs